

DRIVING VALUE AND OUTCOMES IN Oncology

AMCP | Academy of Managed Care Pharmacy®

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. Commercial purposes include but are not limited to symposia, educational programs, and other forms of presentation, whether developed or offered by for-profit or not-for-profit entities, and that involve funding from for-profit firms or a registration fee that is other than nominal. In addition, organizations may not widely redistribute or re-use this webinar material without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. This includes large quantity redistribution of the material or storage of the material on electronic systems for other than personal use.

Welcome


Moderator
Rami Rihani, PharmD
Administrator of Pharmacy and Chronic Disease Management
Advocate Health Care

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

DRIVING VALUE AND OUTCOMES IN **Oncology** AMCP Academy of Managed Care Pharmacy®

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

How to Ask a Question



Type your question in the "Questions" area

Now
Webinar ID: 158-614-635
GoToWebinar

Today's Webinar

- Partnership Forum Overview
- Partnership Forum Discussions & Recommendations
 - Opportunities and Challenges in Oncology Valuation
 - Value-Based Contracting in Oncology
 - The Promise of Precision Medicine and Population Health in Oncology
- Conclusion and Q&A

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

Introductions

Presenters

Ann Nguyen, PharmD

Director, Oncology Solutions
Anthem, Inc.

Harold Carter, PharmD

Director, Clinical Solutions
Express Scripts Holding Company

Kellie Meyer, PharmD, MPH

AmerisourceBergen
Senior Director, Global Health Economics
Xcenda

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

Partnership Forum:

An Interactive Program Geared to Develop Solutions

- Executives and professionals from multi-stakeholder groups
 - Representing payers and purchasers, physicians, pharma and biotech, oncology professional associations, health systems, consultants, and researchers
- 1½-days of didactic/interactive presentations, panel discussions, and workshop breakout groups
- Summary proceedings published in JMCP and at <http://www.amcp.org/OncologyPartnershipForum/>

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

**DRIVING VALUE
AND OUTCOMES IN**

Oncology

AMCP | Academy of
Managed Care
Pharmacy*

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016


Background & Key Trends: Defining Value and Outcomes in Oncology

Speaker: Gary Owens, MD

Goal: Provide an overview of value and how to measure it (outcomes), have become the central topic in cancer care. Costs and treatment innovations are conflicting realities that are driving the oncology community to adopt measureable value-based solutions in oncology. Highlight some of the reasons for rising cancer care costs.


At Least 27% More in Cancer Care Costs in 2020 Compared with 2010

- Cancer-related health expenditures being driven by:
 - Greater incidence of cancer: Baby-boom demographics
 - Greater survivorship owing to newer, effective treatments
 - Increased utilization of new technologies, often at higher cost



AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

Cancer Therapy Costs Increasing Over the Decades



AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

Several Approaches to Value in Oncology

TABLE 1: Several Oncology Value Assessment Approaches		
Organization	Name of Tool/Approach	Definition or Value Assessment Approach
Institute of Medicine	N/A	Definition of value in oncology has six separate components: safety, effectiveness, timeliness, patient centeredness, efficiency, and equity. ¹⁰
American Society of Clinical Oncology (ASCO)	Value Framework*	Calculates a "net health benefit" based on clinical effectiveness, toxicity, and additional improvements in treatment-free interval, cancer symptoms, survival curve, or quality of life. ¹¹
National Comprehensive Cancer Network (NCCN)	NCCN Evidence Blocks™	Considers treatment efficacy, safety, quality and consistency of evidence supporting the guideline-based therapy or regimen, and its affordability, as a pictogram so that treatment choices can be informed by the patient's own values. ¹²
Memorial Sloan Kettering (MSK)	DrugAbacus	Calculates the "Abacus Price" or relative value of an intervention, based on efficacy, toxicity, innovative nature of the therapy, cost of development, the frequency of the disease, unmet need, prognosis, and the population burden of disease. ¹³
Institute for Clinical and Economic Review (ICER)	N/A	Not an oncology-specific value framework, but has published assessments of multiple myeloma, non-small cell lung cancer, and prostate cancer. Reviews performed by ICER result in the estimation of cost-effectiveness ratios (cost per quality-adjusted life-year). ¹⁴

*ASCO's Value Framework is still being tested and is not ready for use in clinical settings.¹⁵
N/A = Not applicable.

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

DRIVING VALUE
AND OUTCOMES IN

Oncology

AMCP | Academy of
Managed Care
Pharmacy*

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

Opportunities and Challenges in Oncology Valuation

Panel and Discussion

- Kimberly Westrich, Vice President, Health Services Research, NPC
- Stephen Grubbs, MD, Vice President of Clinical Affairs, ASCO
- Ann Nguyen PharmD, Oncology Solutions Director, Anthem
- Andrew Yu, PharmD, BCOP, Oncology Clinical Coordinator, Group Health

Goal: Provide insights into the various initiatives, tools and models impacting oncology management including, clinical decision support tools, value frameworks, formulary management processes, total cost of care, collaboration with providers, pay-for-value programs and implementing pathways. Identify opportunities to improve oncology outcomes and affordability.

**DRIVING VALUE
AND OUTCOMES IN**

Oncology

AMCP | Academy of
Managed Care
Pharmacy®

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

Breakout Session #1: Defining Value and Outcomes in Oncology

- What are the top oncology management challenges for managed care decision makers?
- How are payers' goals for oncology management evolving and how successful they are in achieving those goals?
- What role do oncology pathways and frameworks play in product evaluation, quality, and cost containment?

Challenges in Oncology Valuation

Disease Related	Information Related	Structure Related
Definition of value	Data collection on outcomes of interest	Value assessment tools are not ready
Not a single disease	Actionable real-world data/evidence	Patient centeredness
Acute to chronic care	Consistency in pathways/guidelines across payers and providers	Aligning incentives
Economic dispassion	Genomic sequencing	Data and value fragmentation
Outcomes of importance	Cancer treatment is complex	Account for new innovations
Palliative care		

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016 •

Opportunities in Oncology Valuation

- Multi-stakeholder certification process for clinical pathways and create additional structure
 - Publish best practices around implementation and data collection
- Emphasize the use of palliative care
 - Improve communications between providers and patients regarding benefits
- Define quality and expectations for quality in oncology to guide biopharmaceutical development and research
 - Create standards for oncology cost-effectiveness studies
 - Develop an oncology dossier, which can support the use of value frameworks and pathways
- Organize individual drug-based formulary dossiers by disease state, to encourage exploration of comparative value by decision makers
- Disseminate information from other countries on value-based efforts in oncology
- Engage patients on the value in cancer care, adding transparency

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

DRIVING VALUE
AND OUTCOMES IN

Oncology

AMCP | Academy of
Managed Care
Pharmacy®

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

Value-Based Contracting in Oncology

Panel and Discussion

- Harold Carter, Pharm D, Express Scripts
- Tim Chiu, PharmD, BCPS, Kaiser Permanente
- Michelle Drozd, PhARMA
- Jacque Mallender, Optimity Advisors

Goal: Outcomes-based/risk-based contracting is the latest example of innovative value-based partnerships that are taking place between payers and manufacturers in an effort to more closely align pharmaceutical cost with drug efficacy. Four stakeholder perspectives on the opportunities and challenges with setting up, measuring and the use of outcomes-based/risk-based in oncology in the US and internationally.

**DRIVING VALUE
AND OUTCOMES IN**

Oncology

AMCP | Academy of
Managed Care
Pharmacy*

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

Breakout Session #2: Outcomes-based/Risk-based contracting in Oncology

- What are the current challenges or barriers with outcomes-based contracting in oncology?
- What changes/improvements in data infrastructure are needed?
- What methodology is currently used and are there gaps that need to be addressed in the analytical models?

Challenges in Value-Based Contracting

Legal	Measurement	Transparency
Open communication	Exchanging information	Information asymmetry
Average-sales price and best-price reporting requirements	Meaningful and measurable outcomes	Contract evaluation and audit
	Consider the patient	Outcomes analysis
	Operational complexity	
	Data availability & accuracy	
	Best practices	

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016 •

Opportunities in Value-Based Contracting

- Publish best practices in contracting for oncology services
 - How to administer the contract program and the infrastructure needed
- Aggregate contract data to add transparency and help improve value-based contracting practices
- Focus lobbying efforts on:
 - Regulatory barriers, including best price regulations and the creation of new safe harbors
 - Against restrictions that could inhibit indication-based pricing
- Advocate for consistent outcome measures in value-based contracts and practical and measurable outcomes
- Patient-reported outcomes

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

DRIVING VALUE
AND OUTCOMES IN

Oncology

AMCP | Academy of
Managed Care
Pharmacy*

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

The Promise of Precision Medicine in Oncology

Speaker: Rachel Anhorn, PharmD

Goal: To provide an overview of precision medicine and how it will change the way we treat patients with cancer in 2017 and beyond. Genomic information has already helped to shape the development and use of some of the newest cancer treatments. And after decades of research, we are poised to enter a new era of medical practice where detailed genetic and molecular information about a patient's cancer is routinely available for effective, patient-specific treatment decisions.

**DRIVING VALUE
AND OUTCOMES IN**

Oncology

AMCP | Academy of
Managed Care
Pharmacy®

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

Breakout Session #3: Precision Medicine

- What will managed care organizations need to change to take advantage of precision medicine advances?
- How do we integrate precision medicine into healthcare delivery?
- Discuss and identify ways to balance population management principles with precision medicine advances.

Challenges in Precision Medicine

Preparation	Utilization	Evolution
Staying current with new evidence	Integrating decision support tools	Small RCTs
Aligning with the medical benefit	Broad genomic testing or specific diagnostics	Greater regulatory focus
Managing expectations	Interpreting genetic testing reports	Generating RWE
Companion diagnostic tests	Defining experimental therapy	Balancing population management with precision medicine

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

Opportunities in Precision Medicine

- Precision medicine can help increase the precision of population health management.
- Educate payers and providers about the pipeline for new genetic testing and targeted oncology medications
- Develop a source of credible, professional information for patients regarding precision medicine and genetic testing
- Find ways to expedite the PA process (ePA)
- Advocate for sensible regulation in terms of genomic testing and companion diagnostics
- Help reach out to laboratories and lab testing associations to communicate managed care challenges

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

Next Steps

- Proceedings publication in JMCP: May issue
- Annual Meeting – Specialty Pharmacy Connect
 - The New Era of Precision Medicine in Oncology
 - The Promise of Big Data in Improving Cancer Care
- Partnership Forums
 - Oncology Partnership Forum
 - Outcomes Based Contracting
 - Precision Medicine
- Evaluation of eDossier for oncology specific updates

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •

Audience Survey Question

Q: Oncology Management covers numerous topics, which one of the below topics is of most interest and importance to you in 2017?

1. Define measureable outcomes for quality measures in oncology.
2. End-to-end management of cancer care
3. Patient financial toxicity of cancer care
4. Value in end of life cancer care – palliative care

AMCP PARTNERSHIP FORUM •
NOVEMBER 15-16, 2016 •


DRIVING VALUE
AND OUTCOMES IN

Oncology

AMCP Academy of
Managed Care
Pharmacy®

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

How to Ask a Question



Type your question in the "Questions" area

File View Help

Audio

Telephone

Mic & Speakers [Settings](#)

MUTED

Questions

[Enter a question for staff]

Send

Now
Webinar ID: 158-614-635
GoToWebinar

**DRIVING VALUE
AND OUTCOMES IN** **Oncology** **AMCP** Academy of
Managed Care
Pharmacy®

AMCP PARTNERSHIP FORUM • NOVEMBER 15-16, 2016

Thank You to Our Sponsors

abbvie AMGEN Bristol-Myers Squibb Celgene FOUNDATION
MEDICINE™

ION Solutions AmerisourceBergen janssen Oncology Lilly National
Pharmaceutical
Council

NOVARTIS PHARMACEUTICALS PARMA RESEARCH • PROGRESS • MORE SANOFI Takeda ONCOLOGY Xcenda®
AmerisourceBergen